Todos Medical Retains Moneta Advisory Partners as
Post# of 1418
(Total Views: 314)
Posted On: 06/21/2022 1:07:20 PM
Todos Medical Retains Moneta Advisory Partners as Strategic Advisors for National Exchange Listing and 3CL Pharma Spinoff
New York, NY, and Tel Aviv, ISRAEL, June 21, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that it has retained Moneta Advisory Partners (“Moneta”) to act as strategic advisors for the Company’s planned listing on a national exchange and the crowdfunding for the Company’s COVID and Long COVID theragnostics-focused joint venture 3CL Pharma. 3CL Pharma is the developer of the Phase 2/3-stage dual mechanism (3CL protease inhibitor and anti-cytokine) therapeutics candidate Tollovir™ for the treatment of hospitalized COVID-19 patients and the distributor of Tollovid®, the proprietary 3CL protease inhibitor immune support dietary supplement currently available on Amazon and www.MyTollovid.com.
“Recent case studies reporting that the Company’s dietary supplement product Tollovid was able to help those users deal with many of their Long COVID-related symptoms really brought to light the tremendous first mover advantage 3CL Pharma has in this quickly emerging Long COVID healthcare market,” said Jon Najarian, Managing Partner at Moneta. “I’ve been following the Tollovid story for some time. I myself used the Tollovid Max version of the product for a week during the early winter period and I believe it made a big difference for me. With the emergence of Long COVID as a potentially enormous public healthcare problem negatively impacting individual freedom, worker productivity and driving huge numbers of people towards disability, now is the time for action.”
“The Moneta team is very well positioned to help Todos get to the next level,” said Gerald Commissiong, President & CEO at Todos Medical. “We intend to work very closely with them in the months ahead as we move towards a national exchange listing for Todos and a crowdfunding for 3CL Pharma that already has over 8,000 customers who have purchased Tollovid with generally very favorable results.”
https://investor.todosmedical.com/news-events...-strategic
New York, NY, and Tel Aviv, ISRAEL, June 21, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that it has retained Moneta Advisory Partners (“Moneta”) to act as strategic advisors for the Company’s planned listing on a national exchange and the crowdfunding for the Company’s COVID and Long COVID theragnostics-focused joint venture 3CL Pharma. 3CL Pharma is the developer of the Phase 2/3-stage dual mechanism (3CL protease inhibitor and anti-cytokine) therapeutics candidate Tollovir™ for the treatment of hospitalized COVID-19 patients and the distributor of Tollovid®, the proprietary 3CL protease inhibitor immune support dietary supplement currently available on Amazon and www.MyTollovid.com.
“Recent case studies reporting that the Company’s dietary supplement product Tollovid was able to help those users deal with many of their Long COVID-related symptoms really brought to light the tremendous first mover advantage 3CL Pharma has in this quickly emerging Long COVID healthcare market,” said Jon Najarian, Managing Partner at Moneta. “I’ve been following the Tollovid story for some time. I myself used the Tollovid Max version of the product for a week during the early winter period and I believe it made a big difference for me. With the emergence of Long COVID as a potentially enormous public healthcare problem negatively impacting individual freedom, worker productivity and driving huge numbers of people towards disability, now is the time for action.”
“The Moneta team is very well positioned to help Todos get to the next level,” said Gerald Commissiong, President & CEO at Todos Medical. “We intend to work very closely with them in the months ahead as we move towards a national exchange listing for Todos and a crowdfunding for 3CL Pharma that already has over 8,000 customers who have purchased Tollovid with generally very favorable results.”
https://investor.todosmedical.com/news-events...-strategic
(1)
(0)